Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Warren

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Plos One|September 17, 2013
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stressCarlos Farkas, Carla P Martins, David Escobar, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 6, 2024
Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastasesTommaso Pollini, Thuy Tran, Paul Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activityVered Stearns, Ann Gallagher, Celina G Kleer, et al.
Biomedical Optics Express|May 9, 2012
Tissue phantoms in multicenter clinical trials for diffuse optical technologiesAlbert E Cerussi, Robert Warren, Brian Hill, et al.
Breast Cancer Research and Treatment|October 27, 2010
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerClaudine Isaacs, Pia Herbolsheimer, Minetta C Liu, et al.
Nature Cell Biology|May 26, 2015
RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growthPhilippe Depeille, Linda M Henricks, Robert A H van de Ven, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2016
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and SafetyMargaret E Gatti-Mays, David Venzon, Claudia E Galbo, et al.
Plos Computational Biology|November 24, 2020
Transforming the study of organisms: Phenomic data models and knowledge basesAnne E Thessen, Ramona L Walls, Lars Vogt, et al.
Breast Cancer Research and Treatment|October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxanePaula R Pohlmann, Deena Graham, Tianmin Wu, et al.
The American Journal of Cardiology|October 1, 2013
Relation of electrocardiographic changes in pulmonary embolism to right ventricular enlargementPaul D Stein, Fadi Matta, Michel J Sabra, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Plos One|September 17, 2013
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stressCarlos Farkas, Carla P Martins, David Escobar, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 6, 2024
Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastasesTommaso Pollini, Thuy Tran, Paul Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activityVered Stearns, Ann Gallagher, Celina G Kleer, et al.
Biomedical Optics Express|May 9, 2012
Tissue phantoms in multicenter clinical trials for diffuse optical technologiesAlbert E Cerussi, Robert Warren, Brian Hill, et al.
Breast Cancer Research and Treatment|October 27, 2010
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerClaudine Isaacs, Pia Herbolsheimer, Minetta C Liu, et al.
Nature Cell Biology|May 26, 2015
RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growthPhilippe Depeille, Linda M Henricks, Robert A H van de Ven, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2016
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and SafetyMargaret E Gatti-Mays, David Venzon, Claudia E Galbo, et al.
Plos Computational Biology|November 24, 2020
Transforming the study of organisms: Phenomic data models and knowledge basesAnne E Thessen, Ramona L Walls, Lars Vogt, et al.
Breast Cancer Research and Treatment|October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxanePaula R Pohlmann, Deena Graham, Tianmin Wu, et al.
The American Journal of Cardiology|October 1, 2013
Relation of electrocardiographic changes in pulmonary embolism to right ventricular enlargementPaul D Stein, Fadi Matta, Michel J Sabra, et al.
Pageof 10